Brief: Paion End-Sept Cash And Cash Equivalents At EUR 22.8 Million
Nov 6 (Reuters) - PAION AG PA8G.DE :
* PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE
MONTHS OF
2019
* CASH AND CASH EQUIVALENTS OF EUR 22.8 MILLION AS OF 30
SEPTEMBER
2019
* NDA FOR REMIMAZOLAM ACCEPTED FOR REVIEW BY FDA - PDUFA
DATE SET
FOR 05 APRIL 2020
Source text for Eikon: ID:nEQbgLvf3a
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022